The emergence of targeted therapy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) paradigms has radically changed advanced NSCLC treatment and improved patient survival rates, especially for advanced lung adenocarcinoma (3). Here, EGFR is linked to lung adenocarcinoma.